EU and US could reach trade deal this weekend - Reuters
On Tuesday, Citizens JMP raised the price target for DBV Technologies S.A (NASDAQ:DBVT) shares to $21.00, up from the previous $15.00, while maintaining a Market Outperform rating. DBV Technologies’ stock has seen a significant increase, soaring over 190% year-to-date, with InvestingPro data showing an impressive 174% gain in the past six months alone. The surge is attributed to a series of positive developments that have bolstered investor confidence. According to InvestingPro’s Fair Value analysis, the stock appears to be trading near its fair value, with analyst targets ranging from $16.06 to $21.09.
The analyst at Citizens JMP highlighted several key factors contributing to the optimistic outlook for DBVT. Firstly, three-year data for 1-3-year-olds demonstrated that the safety and efficacy of Viaskin Peanut™, the company’s flagship product, improve over time. Additionally, DBVT’s presentation at the American Academy of Allergy, Asthma & Immunology (AAAAI) attracted a standing-room-only audience, indicating strong interest in the product.
Another critical development that has positively impacted DBVT’s valuation is the agreement with the FDA that the Phase 3 VITESSE trial for 4-7-year-olds will satisfy the agency’s safety database requirements. This agreement eliminates the need for a previously planned safety study, streamlining the path to potential approval.
The performance of Xolair™ in the food allergy market has also been a positive indicator for DBVT. Within a year of its launch, over 50,000 individuals are using Xolair, and only 10% of those are within Viaskin Peanut™’s target demographic of 1-7-year-old peanut allergy patients. This uptake demonstrates a substantial market opportunity and suggests that allergists are open to prescribing new therapies, despite complaints about Xolair’s high cost and reimbursement challenges.
In light of Xolair’s successful launch, Citizens JMP is accelerating its launch curve projections for Viaskin Peanut. The firm’s conservative estimates now anticipate approximately 31,000 4-7-year-olds and 28,000 1-3-year-olds using the patch after one year on the market, which could be an underestimate given Xolair’s rapid adoption.
Despite the positive developments, Citizens JMP has adjusted its launch timeline for Viaskin Peanut, pushing back the projected launch for 1-3-year-olds from late 2027 to early 2028 in the U.S. and from 2028 to 2029 in the EU. DBVT is set to begin the 6-month COMFORT Toddlers safety study this quarter, aiming to enroll around 480 individuals. The firm remains confident in DBVT’s execution capabilities, anticipating a Biologics License Application (BLA) submission in the second half of 2026, which could align with the new projected launch dates.
Citizens JMP maintains its forecast of over $2 billion in peak sales for DBVT, underscoring a strong financial outlook for the company’s future. Currently, DBVT has a market capitalization of $251.32 million and operates with a moderate level of debt. For deeper insights into DBVT’s financial health and growth potential, InvestingPro subscribers can access the comprehensive Pro Research Report, which is part of our coverage of over 1,400 US equities.
In other recent news, DBV Technologies has seen significant developments that are capturing the attention of investors. H.C. Wainwright has increased its price target for the company to $16.00, up from $7.00, maintaining a Buy rating due to positive evaluations of its epicutaneous immunotherapy platform, particularly the Viaskin Peanut product. This follows encouraging data from studies involving toddlers and regulatory alignment for trials in older children. Meanwhile, JMP Securities has maintained a Market Outperform rating with a $10.00 price target, citing optimism around upcoming clinical trials. Notably, DBV Technologies plans to initiate the COMFORT safety trial for toddlers and anticipates releasing results from the VITESSE trial for older children by late 2025.
The U.S. FDA has agreed that the VITESSE trial will provide sufficient safety data for potential approval for children aged 4-7, with a Biologics License Application expected in the first half of 2026. Despite these promising developments, DBV Technologies has disclosed a potential cash shortage, indicating that its current reserves may only last until April. The company is actively seeking additional capital but faces uncertainty about securing favorable terms. Analysts highlight the significant unmet need for effective peanut allergy treatments, positioning Viaskin Peanut as a promising solution due to its non-invasive administration and safety profile.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.